GGrantIndex
← Search

CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET

$3,235M01FY2009RRNIH

Pennsylvania State Univ Hershey Med Ctr, Hershey PA

Investigators

Linked publications, trials & patents

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to compare the effects of paclitaxel in combination with bevacizumab or paclitaxel alone in patients with breast cancer that has spread or reocurred.

View original record on NIH RePORTER →
CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET · GrantIndex